Articles by tag: biotech

Vyjuvek gene gel treatment butterfly disease DEB 2026

UK approves Vyjuvek gene gel for wound treatment in dystrophic epidermolysis bullosa. Efficacy 67% at 6 months. Learn mechanism of action and prospects.

Gene therapy OPGx-LCA5 accepted into FDA RDEP program

Learn how Opus Genetics' gene therapy OPGx-LCA5 received RDEP status from the FDA, accelerating the development of treatment for ultra-rare LCA5 blindness in children. Detailed analysis and prospects.